Arvinas & Novartis have signed an exclusive strategic license agreement for the development & commercialization of the former’s ARV-766, Protac AR degrader, globally for prostate cancer as well as an asset purchase agreement for AR-V7’s (preclinical asset) sale to Novartis
Under the collaboration, Novartis will handle ARV-766’s global clinical development & commercialization plus gain all the rights to research, develop, manufacture & commercialize AR-V7
Furthermore, Arvinas is entitled to receive $150.0M up front under the asset purchase agreement and an additional ~$1.01B as development, regulatory & commercial milestones plus ARV-766 related tiered royalties through the license agreement
Ref: Arvinas | Image: Arvinas
Related News:- Carrick Therapeutics Entered into a Clinical Trial Collaboration and Supply Agreement with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
